The incredible success of the drive to develop and deploy vaccines against COVID-19 – despite the very real logistical issues that continue to beset the process here in the U.S. and elsewhere in the world – stands as a triumph of science and public health. There are now three vaccines authorized for use, but the push to discover and develop new ones continues. We spoke with Professor Frances Lund of the University of Alabama at Birmingham. Lund is Charles H. McCauley Professor and Chair of the Department of Microbiology at UAB and played a key role in the development of a new vaccine candidate, adCOVID – a vaccine that unlike the others currently in use for COVID is intranasal – which began its phase one clinical trial in late February. We spoke with her about what intranasals mean and why they might be the future of the fight against COVID.